CASI Pharmaceuticals focuses on building a pipeline through mutually beneficial business development transactions. The Company's strategy leverages its resources and expertise in China to develop and commercialize innovative products in China and other markets.
TypePublic
HQRockville, US
Founded1991
Size (employees)26 (est)+30%
Websitecasipharmaceuticals.com
CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at CASI Pharmaceuticals

Sara Capitelli

Sara Capitelli

Vice President, Finance and Principal Accounting Officer

CASI Pharmaceuticals Office Locations

CASI Pharmaceuticals has offices in Rockville and Beijing
Rockville, (HQ)
300 9620 Medical Center Dr
Beijing,
CASI (Beijing) Pharmaceuticals, Inc. FullLink Plaza Suite B1214, B1215 18 Chaoyangmenwai Street, Chaoyang
Show all (2)
Report incorrect company information

CASI Pharmaceuticals Financials and Metrics

CASI Pharmaceuticals Revenue

CASI Pharmaceuticals's revenue was reported to be $47.71 k in FY, 2015 which is a 101.1% increase from the previous period.
USD

Net income (Q3, 2018)

(8.8m)

Market capitalization (4-Dec-2018)

400.6m

Closing stock price (4-Dec-2018)

4.3

Cash (30-Sep-2018)

98.9m

EV

303.2m
CASI Pharmaceuticals's current market capitalization is $400.6 m.
Annual
USDFY, 2013FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

23.7k47.7k

Revenue growth, %

(100%)101%

Cost of goods sold

7.5k6.3k

Gross profit

16.3k41.4k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cost of goods sold

6.3k2.7k

General and administrative expense

648.7k891.4k891.9k1.2m924.8k857.6k673.9k765.1k1.9m676.9k644.2k691.4k625.9k1.3m4.0m6.9m

R&D expense

793.8k560.0k724.5k697.0k865.0k1.2m942.3k1.0m1.4m1.0m1.0m1.7m971.0k1.7m1.7m1.8m

Operating expense total

1.4m1.5m1.6m1.8m1.8m2.1m1.6m1.8m3.3m1.7m1.7m2.4m1.6m3.0m8.8m8.7m
Annual
USDY, 2009Y, 2010Y, 2011Y, 2012FY, 2013Y, 2013Y, 2014Y, 2015FY, 2015FY, 2016FY, 2017

Cash

6.3m4.9m1.1m8.0m15.1m15.1m10.7m5.1m5.1m27.1m43.5m

Accounts Receivable

Inventories

Current Assets

15.4m15.4m11.0m5.6m5.6m27.4m43.8m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(5.7m)(26.2m)(7.2m)(9.5m)(10.8m)

Depreciation and Amortization

17.4k48.2k68.4k66.5k117.8k

Inventories

Accounts Payable

(102.4k)352.2k129.5k180.5k849.4k
Quarterly
USDY, 2018

EV/CFO

-23.5 x

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

CASI Pharmaceuticals News and Updates

CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (Trademark: EVOMELA®)

ROCKVILLE, Md., Dec. 3, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in China and throughout the world,...

CASI Pharmaceuticals To Build GMP Manufacturing Site In Wuxi, China

ROCKVILLE, Md., Nov. 16, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in China and throughout the world, ...

Laurus Labs transfers USFDA approved HBV ANDA to CASI Pharmaceuticals

The TDF is prescribed for the treatment of Hepatitis B virus (HBV). There are more than 90 million chronic carriers of hepatitis B in China which accounts for roughly one-third of all HBV chronic carriers in the world with TDF currently the first line therapy.

CASI Pharmaceuticals Announces $48.5 Million Private Placement

ROCKVILLE, Md., Sept. 14, 2018 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout ...
Report incorrect company information

CASI Pharmaceuticals Company Life and Culture

Report incorrect company information

CASI Pharmaceuticals Frequently Asked Questions

  • When was CASI Pharmaceuticals founded?

    CASI Pharmaceuticals was founded in 1991.

  • Who are CASI Pharmaceuticals key executives?

    CASI Pharmaceuticals's key executives are Sara Capitelli.

  • How many employees does CASI Pharmaceuticals have?

    CASI Pharmaceuticals has 26 employees.

  • Who are CASI Pharmaceuticals competitors?

    Competitors of CASI Pharmaceuticals include Generex Biotechnology, Vitality Biopharma and Opiant Pharmaceuticals.

  • Where is CASI Pharmaceuticals headquarters?

    CASI Pharmaceuticals headquarters is located at 300 9620 Medical Center Dr, Rockville.

  • Where are CASI Pharmaceuticals offices?

    CASI Pharmaceuticals has offices in Rockville and Beijing.

  • How many offices does CASI Pharmaceuticals have?

    CASI Pharmaceuticals has 2 offices.